Impact of solid cancer on in-hospital mortality overall and among different subgroups of patients with COVID-19: a nationwide, population-based analysis

Autor: Mariana Brandão, Sylvie Rottey, Evandro de Azambuja, Annouschka Laenen, Hans Wildiers, Peter Vuylsteke, Annemie Rutten, Sandrine Aspeslagh, Christel Fontaine, Joelle Collignon, Willem Lybaert, Jolanda Verheezen, Jean-Charles Goeminne, Wim Demey, Dominique Van Beckhoven, Jessika Deblonde, Tatjana Geukens, Kevin Punie, Kristof Bafort, Leïla Belkhir, Nathalie Bossuyt, Vincent Colombie, Christine Daubresse, Nicolas Dauby, Paul De Munter, Didier Delmarcelle, Mélanie Delvallee, Rémy Demeester, Quentin Delefortrie, Thierry Dugernier, Xavier Holemans, Ingrid Louviaux, Pierre Yves Machurot, Philippe Minette, Saphia Mokrane, Catherine Nachtergal, Séverine Noirhomme, Denis Piérard, Camelia Rossi, Carole Schirvel, Erica Sermijn, Frank Staelens, Filip Triest, Nina Van Goethem, Jens Van Praet, Anke Vanhoenacker, Roeland Verstraete, Elise Willems, Chloé Wyndham-Thomas

Publikováno v: ESMO Open, Vol 5, Iss 5 (2020)

Background Cancer seems to have an independent adverse prognostic effect on COVID-19-related mortality, but uncertainty exists regarding its effect across different patient subgroups. We report a population-based analysis of patients hospitalised wit

Externí odkaz: https://doaj.org/article/586fe84f159e4f27b3ba8735f5cd5063

Cell-free DNA profiling of metastatic prostate cancer reveals microsatellite instability, structural rearrangements and clonal hematopoiesis

Autor: Markus Mayrhofer, Bram De Laere, Tom Whitington, Peter Van Oyen, Christophe Ghysel, Jozef Ampe, Piet Ost, Wim Demey, Lucien Hoekx, Dirk Schrijvers, Barbara Brouwers, Willem Lybaert, Els Everaert, Daan De Maeseneer, Michiel Strijbos, Alain Bols, Karen Fransis, Steffi Oeyen, Pieter-Jan van Dam, Gert Van den Eynden, Annemie Rutten, Markus Aly, Tobias Nordström, Steven Van Laere, Mattias Rantalainen, Prabhakar Rajan, Lars Egevad, Anders Ullén, Jeffrey Yachnin, Luc Dirix, Henrik Grönberg, Johan Lindberg

Publikováno v: Genome Medicine, Vol 10, Iss 1, Pp 1-13 (2018)

Abstract Background There are multiple existing and emerging therapeutic avenues for metastatic prostate cancer, with a common denominator, which is the need for predictive biomarkers. Circulating tumor DNA (ctDNA) has the potential to cost-efficient

Externí odkaz: https://doaj.org/article/4783b889dd4d4c3c8abf60a59cf0a086

Supplementary Table from First-In-Human Phase I Study of the OX40 Agonist MOXR0916 in Patients with Advanced Solid Tumors

Autor: Lillian L. Siu, Ina Rhee, Mahrukh Huseni, Jeong Kim, Maria Anderson, Tony Pourmohamad, Eric Stefanich, Shang-Chiung Chen, Deepali Rishipathak, Mario Sznol, Annemie Rutten, Alexander M. Lesokhin, Laura Q. Chow, Andres Cervantes, Wilson H. Miller, Grant A. McArthur, F. Stephen Hodi, D. Ross Camidge, Ahmad Awada, Michael Gordon, Yung-Jue Bang, Michael J. Pishvaian, Maria J. de Miguel Luken, Howard A. Burris, Tae Won Kim

Supplementary Table from First-In-Human Phase I Study of the OX40 Agonist MOXR0916 in Patients with Advanced Solid Tumors

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0c7045a3205e3b86a9869343e3c0f1eb
https://doi.org/10.1158/1078-0432.22486667.v1

Supplementary Data from First-In-Human Phase I Study of the OX40 Agonist MOXR0916 in Patients with Advanced Solid Tumors

Autor: Lillian L. Siu, Ina Rhee, Mahrukh Huseni, Jeong Kim, Maria Anderson, Tony Pourmohamad, Eric Stefanich, Shang-Chiung Chen, Deepali Rishipathak, Mario Sznol, Annemie Rutten, Alexander M. Lesokhin, Laura Q. Chow, Andres Cervantes, Wilson H. Miller, Grant A. McArthur, F. Stephen Hodi, D. Ross Camidge, Ahmad Awada, Michael Gordon, Yung-Jue Bang, Michael J. Pishvaian, Maria J. de Miguel Luken, Howard A. Burris, Tae Won Kim

Supplementary Data from First-In-Human Phase I Study of the OX40 Agonist MOXR0916 in Patients with Advanced Solid Tumors

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0528c7584af822078d30d2eaa31153f3
https://doi.org/10.1158/1078-0432.22486697.v1

Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial

Autor: Koji Kawai, Satoshi Nagamori, Katherine M Bell-McGuinn, Cristiano Ferrario, Wen Pin Su, Isabel Syndikus, Aude Flechon, Georgios Gakis, Timothy Dudley Clay, Leticia Vazquez Cortés, Ronald de Wit, Florence Joly, Bozena Sikora-Kupis, Sergio Bracarda, Astra M. Liepa, Annemie Rutten, Daniel P. Petrylak, Su Peng Yeh, Annamaria Zimmermann, Sameera R. Wijayawardana, Mutsushi Kawakita, Siobhan Ng, Thean Hsiang Tan, Chikara Ohyama, Yu Jung Kim, Yuriy Golovko, Dimitrios Mavroudis, Jian Ri Li, Reinoud J. B. Blaisse, Mustafa Erman, Francesca Russo, Catherine Becht, Anghel Adrian Udrea, Robert Huddart, Syed A. Hussain, Fransiscus L.G. Erdkamp, Satoshi Fukasawa, Francesco Massari, Motohide Uemura, Boris Alekseev, Irfan Cicin, Se Hoon Park, Marcello Tucci, Lajos Géczi, Maureen J.B. Aarts, Yu Li Su, Fumimasa Fukuta, Hyo Jin Lee, Wolfgang Schultze-Seemann, Alexandra Drakaki, Hakan Harputluoglu, Xavier Garcia del Muro, Santhanam Sundar, Avivit Peer, Herlinde Dumez, William E. Lawler, Juan Ignacio Delgado Mignorance, Naveed Sarwar, Jeanny B. Aragon-Ching, Benjamin T. Herms, Fredrik Laestadius, Nobuaki Matsubara, Ivan Sinielnikov, Cora N. Sternberg, Hiroyuki Nishiyama, Piotr Tomczak, Brigitte Laguerre, Rebecca R. Hozak, Vasilis Karavasilis, Christina A. Schwentner, Hiroyuki Tsunemori, Masayoshi Nagata, Igor Bondarenko, Andrea Necchi, Yen Chuan Ou, Scott T. Tagawa, Constance Thibault, Richard A. Walgren, Akira Yokomizo, Evan Y. Yu, Alejo Rodriguez-Vida, Sufia Safina, Ulka N. Vaishampayan, János Révész, Aristotelis Bamias, Jae-Lyun Lee, Chien Liang Lin, Thomas W. Flaig, Roman Fomkin, Petr Alexandrovich Karlov, Joanna Wojcik-Tomaszewska, Junichi Inokuchi, Wataru Obara, Haralambos Kalofonos, John D. Hainsworth, Marc-Oliver Grimm, Thomas Eugene Lowe, Pablo Gajate Borau, Simon J. Crabb, Lisa Sengeloev, Junji Yonese, Simon Chowdhury, Elizabeth Jane Hovey, Daniel Castellano, Peter Istvan Acs, Chia-Chi Lin, Claudia Lorena Urzua Flores, Jean-Pascal Machiels, Kim N. Chi, Takahiro Osawa, Nobuo Shinohara, Daniel Kejzman, Günter Niegisch, David Sarid, Yuksel Urun, Yun Gyoo Lee, Oday Hamid, Alina Amalia Herzal, Michael Schenker, Eli Rosenbaum, Enrique Grande, Raya Leibowitz-Amit, Naoto Miyajima, Michiel S. van der Heijden, Shinichi Yamashita, Susanna Yee Shan Cheng, Kazuo Nishimura, Sun Young Rha, Thomas Powles, Hasan Şenol Coşkun, Jens Bedke, Ivor J. Percent, Christos Papandreou, James K. Schwarz, Masafumi Oyama, Giorgio V. Scagliotti, Chong-Xian Pan, Yoshihiko Tomita, Giampaolo Tortora, Stéphane Culine, Suet Lai Shirley Wong, Andrey Semenov, Jennifer L. Cultrera, Niels Viggo Jensen, Michael Stöckle, Katsuyoshi Hashine

Publikováno v: Lancet Oncology, 21(1), 105-120. Lancet Publishing Group
The Lancet. Oncology, Vol. 21, no.1, p. 105-120 (2020)
Lancet oncology, 21(1), 105-120. Elsevier Science
lancet oncology, 21(1), 105-120. Lancet Publishing Group

Background Ramucirumab-an IgG1 vascular endothelial growth factor receptor 2 antagonistplus docetaxel was previously reported to improve progression-free survival in platinum-refractory, advanced urothelial carcinoma. Here, we report the secondary en

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cf61e6c114a1ba3c5764d0e77ad9425a
https://doi.org/10.1016/s1470-2045(19)30668-0